Skip to menu Skip to content Skip to footer
Professor Brian Gabrielli
Professor

Brian Gabrielli

Email: 

Overview

Background

Professor Gabrielli completed his undergraduate education at James Cook University in Townsville and PhD at La Trobe University in Melbourne. After two postdoctoral positions in the USA in the emerging field of cell cycle regulation, he was recruited to establish his own independent research at the Queensland Institute of Medical Research, and then recruited to the Diamantina Institute in 2002, and Mater Research Institute in 2016. He is head of the Smiling for Smiddy Cell Cycle Group.

Research Interests

Mechanisms that regulate cell division, particularly progression into mitosis. These mechanisms are often mutated in cancers and are likely to be major contributors to cancer development. Identifying the genetic mutations that disrupt normal progression and particularly mechanisms, known as checkpoints, provides diagnostic and prognostic opportunities. It also provides potential new targets for chemotherapeutics as drugs targeting defective checkpoints have tumour selective cytotoxic potential.

Research Projects

  • Identifying the molecular basis for defective checkpoints in melanoma.
  • Targeting defective cell cycle responses to ultraviolet radiation, replication stress and TopoII inhibitors in melanoma, and investigating whether the same defects in other cancer types respond to similar targeting.
  • Investigating means of identify very early changes in moles that drive progression to melanoma
  • Targeting Aurora kinases in HPV-driven cancers

Availability

Professor Brian Gabrielli is:
Available for supervision
Media expert

Qualifications

  • Bachelor (Honours) of Science (Advanced), James Cook University
  • Doctor of Philosophy, La Trobe University

Research interests

  • Ultraviolet radiaiton and its contribution to melanoma

  • Targeting defective cell cycle checkpoints in cancers, particularly melanoma

  • Functional genomics; using high throughout screening combined with increased or decreased gene dosage to identify novel regulatory mechanisms and drug targets

  • Mechanism of action studies for novel anti-caner therapeutics

Works

Search Professor Brian Gabrielli’s works on UQ eSpace

159 works between 1984 and 2024

21 - 40 of 159 works

2018

Journal Article

Mechanism of action of the third generation benzopyrans and evaluation of their broad anti-cancer activity in vitro and in vivo

Stevenson, Alexander J., Ager, Eleanor I., Proctor, Martina A., Škalamera, Dubravka, Heaton, Andrew, Brown, David and Gabrielli, Brian G. (2018). Mechanism of action of the third generation benzopyrans and evaluation of their broad anti-cancer activity in vitro and in vivo. Scientific Reports, 8 (1) 22882, 5144. doi: 10.1038/s41598-018-22882-w

Mechanism of action of the third generation benzopyrans and evaluation of their broad anti-cancer activity in vitro and in vivo

2018

Journal Article

Discovery of thalicthuberine as a novel antimitotic agent from nature that disrupts microtubule dynamics and induces apoptosis in prostate cancer cells

Levrier, Claire, Rockstroh, Anja, Gabrielli, Brian, Kavallaris, Maria, Lehman, Melanie, Davis, Rohan A, Sadowski, Martin C and Nelson, Colleen C (2018). Discovery of thalicthuberine as a novel antimitotic agent from nature that disrupts microtubule dynamics and induces apoptosis in prostate cancer cells. Cell Cycle, 17 (5), 652-668. doi: 10.1080/15384101.2017.1356512

Discovery of thalicthuberine as a novel antimitotic agent from nature that disrupts microtubule dynamics and induces apoptosis in prostate cancer cells

2018

Journal Article

Acetylsalicylic acid governs the effect of sorafenib in RAS- mutant cancers

Hammerlindl, Heinz, Ravindran Menon, Dinoop, Hammerlindl, Sabrina, Emran, Abdullah Al, Torrano, Joachim, Sproesser, Katrin, Thakkar, Divya, Xiao, Min, Atkinson, Victoria G., Gabrielli, Brian, Haass, Nikolas K., Herlyn, Meenhard, Krepler, Clemens and Schaider, Helmut (2018). Acetylsalicylic acid governs the effect of sorafenib in RAS- mutant cancers. Clinical Cancer Research, 24 (5), 1090-1102. doi: 10.1158/1078-0432.CCR-16-2118

Acetylsalicylic acid governs the effect of sorafenib in RAS- mutant cancers

2018

Conference Publication

Distinct epigenetic remodelling defines early stress-induced drug tolerance in melanoma

Emran, A., Marzese, D. M., Menon, D. R., Stark, M., Torrano, J., Hammerlindl, H., Zhang, G., Brafford, P., Hammerlindl, S., Gupta, D., Mills, G. B., Lu, Y., Flaherty, K., Sturm, R., Hoon, D. S. B., Gabrielli, B., Herlyn, M. and Schaider, H. (2018). Distinct epigenetic remodelling defines early stress-induced drug tolerance in melanoma. Australasian College of Dermatologists, 51st Annual Scientific Meeting, Gold Coast, QLD, Australia , 19–22 May 2018. Richmond, VIC, Australia: Wiley-Blackwell Publishing. doi: 10.1111/ajd.16_12815

Distinct epigenetic remodelling defines early stress-induced drug tolerance in melanoma

2018

Conference Publication

Targeting cell cycle phase-specific drug sensitivity for melanoma therapy

Daignault, S. M., Hill, D. S., Spoerri, L., Stehbens, S., Weninger, W., Gabrielli, B., Dolcetti, R. and Haass, N. K. (2018). Targeting cell cycle phase-specific drug sensitivity for melanoma therapy. 45th Annual Meeting of the Arbeitsgemeinscha-Dermatologische-Forschung (ADF), Zurich, Switzerland, 7-10 March 2018. Chichester, West Sussex, United Kingdom: Wiley-Blackwell Publishing.

Targeting cell cycle phase-specific drug sensitivity for melanoma therapy

2018

Conference Publication

Overexpression of the cell cycle regulator Emi1 promotes chromosome instability and tumorigenesis

Duijf, Pascal H. G., Vaidyanathan, Srividya, Cato, Kathleen, Thangavelu, Pulari U., Lin, Cheng-Yu, Tang, Lu, Pavey, Sandra, Haass, Nikolas K. and Gabrielli, Brian G. (2018). Overexpression of the cell cycle regulator Emi1 promotes chromosome instability and tumorigenesis. 76th Annual Meeting of the Japanese Cancer Association, Yokohama, Japan, 28-30 September 2017. Tokyo, Japan: Wiley Japan. doi: 10.1111/cas.13499

Overexpression of the cell cycle regulator Emi1 promotes chromosome instability and tumorigenesis

2017

Journal Article

Distinct histone modifications denote early stress-induced drug tolerance in cancer

Emran, Abdullah Al, Marzese, Diego M., Menon, Dinoop Ravindran, Stark, Mitchell S., Torrano, Joachim, Hammerlindl, Heinz, Zhang, Gao, Brafford, Patricia, Salomon, Matthew P., Nelson, Nellie, Hammerlindl, Sabrina, Gupta, Deepesh, Mills, Gordon B., Lu, Yiling, Sturm, Richard A., Flaherty, Keith, Hoon, Dave S. B., Gabrielli, Brian, Herlyn, Meenhard and Schaider, Helmut (2017). Distinct histone modifications denote early stress-induced drug tolerance in cancer. Oncotarget, 9 (9), 8206-8222. doi: 10.18632/oncotarget.23654

Distinct histone modifications denote early stress-induced drug tolerance in cancer

2017

Journal Article

Keratinocyte sonic hedgehog up-regulation drives the development of giant congenital nevi via paracrine endothelin-1 secretion

Chitsazan, Arash, Ferguson, Blake, Villani, Rehan, Handoko, Herlina Y, Mukhopadhyay, Pamela, Gabrielli, Brian, Mooi, Wolter J, Soyer, H Peter, Lambie, Duncan, Khosrotehrani, Kiarash, Morahan, Grant and Walker, Graeme J (2017). Keratinocyte sonic hedgehog up-regulation drives the development of giant congenital nevi via paracrine endothelin-1 secretion. The Journal of investigative dermatology, 138 (4), 893-902. doi: 10.1016/j.jid.2017.10.032

Keratinocyte sonic hedgehog up-regulation drives the development of giant congenital nevi via paracrine endothelin-1 secretion

2017

Journal Article

Inhibition of Aurora A and Aurora B Is Required for the Sensitivity of HPV-Driven Cervical Cancers to Aurora Kinase Inhibitors

Martin, David, Fallaha, Sora, Proctor, Martina, Stevenson, Alexander, Perrin, Lewis, McMillan, Nigel and Gabrielli, Brian (2017). Inhibition of Aurora A and Aurora B Is Required for the Sensitivity of HPV-Driven Cervical Cancers to Aurora Kinase Inhibitors. Molecular Cancer Therapeutics, 16 (9), 1934-1941. doi: 10.1158/1535-7163.MCT-17-0159

Inhibition of Aurora A and Aurora B Is Required for the Sensitivity of HPV-Driven Cervical Cancers to Aurora Kinase Inhibitors

2017

Journal Article

Cell cycle-tailored targeting of metastatic melanoma: challenges and opportunities

Haass, Nikolas K. and Gabrielli, Brian (2017). Cell cycle-tailored targeting of metastatic melanoma: challenges and opportunities. Experimental Dermatology, 26 (7), 649-655. doi: 10.1111/exd.13303

Cell cycle-tailored targeting of metastatic melanoma: challenges and opportunities

2017

Journal Article

Genome-wide overexpression screen identifies genes able to bypass p16-mediated senescence in melanoma

Lee, Won Jae, Skalamera, Dubravka, Dahmer-Heath, Mareike, Shakhbazov, Konstanin, Ranall, Max V., Fox, Carly, Lambie, Duncan, Stevenson, Alexander J., Yaswen, Paul, Gonda, Thomas J. and Gabrielli, Brian (2017). Genome-wide overexpression screen identifies genes able to bypass p16-mediated senescence in melanoma. SLAS Discovery, 22 (3), 298-308. doi: 10.1177/1087057116679592

Genome-wide overexpression screen identifies genes able to bypass p16-mediated senescence in melanoma

2017

Conference Publication

Cell cycle-tailored targeting of metastatic melanoma: challenges and opportunities

Haass, N., Spoerri, L., Tonnessen, C. A., Beaumont, K. A., Hill, D. S., Daignault, S. M., Gabrielli, B. and Weninger, W. (2017). Cell cycle-tailored targeting of metastatic melanoma: challenges and opportunities. Australasian College of Dermatologists 50th Annual Scientific Meeting, International Convention Centre, Sydney, NSW Australia, 6-9 May 2017. Richmond, VIC Australia: Wiley-Blackwell Publishing Asia. doi: 10.1111/ajd.20_12652

Cell cycle-tailored targeting of metastatic melanoma: challenges and opportunities

2017

Journal Article

6α-Acetoxyanopterine: a novel structure class of mitotic inhibitor disrupting microtubule dynamics in prostate cancer cells

Levrier, Claire, Sadowski, Martin C., Rockstroh, Anja, Gabrielli, Brian, Kavallaris, Maria, Lehman, Melanie, Davis, Rohan A. and Nelson, Colleen C. (2017). 6α-Acetoxyanopterine: a novel structure class of mitotic inhibitor disrupting microtubule dynamics in prostate cancer cells. Molecular Cancer Therapeutics, 16 (1), 3-15. doi: 10.1158/1535-7163.MCT-16-0325

6α-Acetoxyanopterine: a novel structure class of mitotic inhibitor disrupting microtubule dynamics in prostate cancer cells

2017

Journal Article

Topoisomerase II inhibitors and poisons, and the influence of cell cycle checkpoints

D'Arcy, Nicholas and Gabrielli, Brian (2017). Topoisomerase II inhibitors and poisons, and the influence of cell cycle checkpoints. Current Medicinal Chemistry, 24 (15), 1504-1519. doi: 10.2174/0929867323666161205122613

Topoisomerase II inhibitors and poisons, and the influence of cell cycle checkpoints

2016

Journal Article

Genome-wide gain-of-function screen for genes that induce epithelial-to-mesenchymal transition in breast cancer

Skalamera, Dubravka, Dahmer-Heath, Mareike, Stevenson, Alexander J., Pinto, Cletus, Shah, Esha T., Daignault, Sheena M., Said, Nur Akmarina B. M., Davis, Melissa, Haass, Nikolas K., Williams, Elizabeth D., Hollier, Brett G., Thompson, Erik W., Gabrielli, Brian and Gonda, Thomas J. (2016). Genome-wide gain-of-function screen for genes that induce epithelial-to-mesenchymal transition in breast cancer. Oncotarget, 7 (38), 61000-61020. doi: 10.18632/oncotarget.11314

Genome-wide gain-of-function screen for genes that induce epithelial-to-mesenchymal transition in breast cancer

2016

Journal Article

Multiparameter analysis of naevi and primary melanomas identifies a subset of naevi with elevated markers of transformation

Fox, Carly, Lambie, Duncan, Wilmott, James S., Pinder, Alex, Pavey, Sandra, Lê Cao, Kim-Anh, Akalin, Taner, Karaarslan, Isil Kilinc, Ozdemir, Fezal, Scolyer, Richard A., Yamada, Miko, Soyer, H. Peter, Schaider, Helmut and Gabrielli, Brian (2016). Multiparameter analysis of naevi and primary melanomas identifies a subset of naevi with elevated markers of transformation. Pigment Cell and Melanoma Research, 29 (4), 444-452. doi: 10.1111/pcmr.12489

Multiparameter analysis of naevi and primary melanomas identifies a subset of naevi with elevated markers of transformation

2016

Journal Article

A mutation in the Cdon gene potentiates congenital nevus development mediated by NRASQ61K

Chitsazan, Arash, Ferguson, Blake, Ram, Ramesh, Mukhopadhyay, Pamela, Handoko, Herlina Y., Gabrielli, Brian, Soyer, Peter H, Morahan, Grant and Walker, Graeme J. (2016). A mutation in the Cdon gene potentiates congenital nevus development mediated by NRASQ61K. Pigment Cell and Melanoma Research, 29 (4), 459-464. doi: 10.1111/pcmr.12487

A mutation in the Cdon gene potentiates congenital nevus development mediated by NRASQ61K

2016

Journal Article

Cell cycle phase-specific drug resistance as an escape mechanism of melanoma cells

Beaumont, Kimberley A., Hill, David S., Daignault, Sheena M., Lui, Goldie Y. L., Sharp, Danae M., Gabrielli, Brian, Weninger, Wolfgang and Haass, Nikolas K. (2016). Cell cycle phase-specific drug resistance as an escape mechanism of melanoma cells. Journal of Investigative Dermatology, 136 (7), 1479-1489. doi: 10.1016/j.jid.2016.02.805

Cell cycle phase-specific drug resistance as an escape mechanism of melanoma cells

2016

Conference Publication

Cell cycle phase-specific drug resistance as an escape mechanism of melanoma cells

Beaumont, K., Hill, D., Daignault, S., Sharp, D., Gabrielli, B., Weninger, W. and Haass, N. (2016). Cell cycle phase-specific drug resistance as an escape mechanism of melanoma cells. Annual Meeting of the Society-for-Investigative-Dermatology (SID), Scottsdale, AZ, United States, 11-14 May 2016. Oxford, United Kingdom: Elsevier. doi: 10.1016/j.jid.2016.02.695

Cell cycle phase-specific drug resistance as an escape mechanism of melanoma cells

2016

Journal Article

A novel ATM-dependent checkpoint defect distinct from loss of function mutation promotes genomic instability in melanoma

Spoerri, Loredana, Brooks, Kelly, Chia, KeeMing, Grossman, Gavriel, Ellis, Jonathan J., Dahmer-Heath, Mareike, Skalamera, Dubravka, Pavey, Sandra, Burmeister, Bryan and Gabrielli, Brian (2016). A novel ATM-dependent checkpoint defect distinct from loss of function mutation promotes genomic instability in melanoma. Pigment Cell and Melanoma Research, 29 (3), 329-339. doi: 10.1111/pcmr.12466

A novel ATM-dependent checkpoint defect distinct from loss of function mutation promotes genomic instability in melanoma

Funding

Current funding

  • 2023 - 2026
    Targeting replication stress to improve immune recognition and reduce immunosuppressive in the tumour microenvironment
    Ovarian Cancer Research Foundation Research Grants
    Open grant

Past funding

  • 2021 - 2024
    Enhancing tumour immune detection by targeting replication stress
    Established Investigator
    Open grant
  • 2018 - 2020
    Towards clinical diagnosis of inflammatory skin rashes using minimally-invasive microsampling techniques
    TRI Spore Grants
    Open grant
  • 2018 - 2019
    Preclinical development of combinations with CHK1 inhibitors in melanoma and lung cancer
    Cancer Council Queensland
    Open grant
  • 2016 - 2019
    Aurora A as a novel therapeutic target for HPV-driven cancers (NHMRC Project Grant administered by Griffith University)
    Griffith University
    Open grant
  • 2016
    Epigenetic remodelling driving acquired permanent drug resistance in melanoma cells
    PA Research Foundation
    Open grant
  • 2015 - 2018
    Defining the role of Microphthalmia-associated Transcription Factor (MITF) in melanoma heterogeneity by real-time cell cycle imaging
    NHMRC Project Grant
    Open grant
  • 2015
    Next-generation cell analysis: Automated high-throughput 3D microscope and multimode microplate reader
    NHMRC Equipment Grant
    Open grant
  • 2015 - 2016
    Novel therapeutic targets for HPV-driven cancers (Cancer Council Queensland grant administered by Griffith University
    Griffith University
    Open grant
  • 2015
    Targeting HPV in oropharyngeal cancers
    PA Research Foundation
    Open grant
  • 2014
    Calibration of single channel and liquid handling robots
    UQ Major Equipment and Infrastructure
    Open grant
  • 2014 - 2016
    Identifying the mechanism of the G2 phase UV checkpoint and repair response commonly defective in melanoma
    NHMRC Project Grant
    Open grant
  • 2014
    Purchase of low O2 incubator and Dissociator
    NHMRC Equipment Grant
    Open grant
  • 2013
    Functional characterization of the regulatory architecture of melanoma-associated loci
    NHMRC Project Grant
    Open grant
  • 2013 - 2015
    Functional characterization of the regulatory architecture of melanoma-associated loci (NHMRC Project Grant administered by Garvan Institute)
    Garvan Institute
    Open grant
  • 2012 - 2015
    Functional assessment of new melanoma genomic mutations
    Worldwide Cancer Research
    Open grant
  • 2012 - 2015
    Determining Predictors of Sensitivity to CHK Inhibitors in Metastatic Melanoma (Cancer Australia grant administered by the University of Melbourne)
    University of Melbourne
    Open grant
  • 2012 - 2013
    Defining a response to UV exposure that is defective in melanoma
    Cancer Council Queensland
    Open grant
  • 2012 - 2015
    Synthetic lethality screen targeting a defective checkpoint in melanoma
    NHMRC Project Grant
    Open grant
  • 2012
    Validation of genes potentially involved in early stage melanoma using immunohistochemistry
    Queensland Pharmacy Research Trust
    Open grant
  • 2011
    Laser Scanner for Biomolecular Imaging
    NHMRC Equipment Grant
    Open grant
  • 2011
    Targeting the G2 phase checkpoint in Glioblastoma to improve the efficacy of current therapy
    Brain Foundation
    Open grant
  • 2010
    Centrosome overduplication contributes to tumorigenesis
    NHMRC Project Grant
    Open grant
  • 2010 - 2015
    NHMRC Research Fellowship: Senior Research Fellowship A
    NHMRC Research Fellowship
    Open grant
  • 2010 - 2012
    Synthetic lethality screen targeting a defective checkpoint in melanoma
    Cancer Council Queensland
    Open grant
  • 2009
    Proteomic studies in cancer, immunology and metabolism research
    UQ Institute Co-Funding
    Open grant
  • 2009 - 2012
    The role of tumour-initiating cells in glioma
    NHMRC Project Grant
    Open grant
  • 2008 - 2009
    Histone deacetylase inhibitors can inhibit tumour growth via induction of an anti-tumour immune response
    Cancer Council Queensland
    Open grant
  • 2008 - 2009
    Is the heterochromatin checkpoint a useful anti-cancer drug target?
    Cancer Council Queensland
    Open grant
  • 2008
    Confocal Microscopy
    UQ Major Equipment and Infrastructure
    Open grant
  • 2007 - 2009
    CDK4 activity in S/G2 phases influences mitotic fidelity
    NHMRC Project Grant
    Open grant
  • 2007 - 2009
    The function of truncated MEK1 in a G2 phase cell cycle delay and in mitosis
    ARC Discovery Projects
    Open grant
  • 2007 - 2009
    Transcriptional complexity of cell cycle regulated genes during cell division and tumorigenesis
    NHMRC Project Grant
    Open grant
  • 2006
    A Facility for High-Throughput, Functional Gene Discovery Using Arrayed Retroviral Expression Cloning
    ARC Linkage Infrastructure, Equipment and Facilities
    Open grant
  • 2006 - 2007
    The molecular basis for the initiation of squamous differentiation
    Queensland Cancer Fund
    Open grant
  • 2005 - 2006
    G2 phase cdk4 activity regulates expression of proteins essential for the fidelity of mitosis: a target for UV-induced p16 expression
    Queensland Cancer Fund
    Open grant
  • 2005 - 2009
    NHMRC SENIOR RESEARCH FELLOWSHIP
    NHMRC Research Fellowship
    Open grant
  • 2004 - 2006
    Function of the unique mitotic form of MEK
    ARC Discovery Projects
    Open grant
  • 2004 - 2006
    Histone Hyperacetylation Affects G2/M Cell Cycle Transition
    NHMRC Project Grant
    Open grant
  • 2004 - 2006
    What Regulates G2 Phase?
    NHMRC Project Grant
    Open grant
  • 2003 - 2004
    Mechanism of UV Induction of the Melanoma Susceptibility Gene Product P16CDKN2A in Skin
    Queensland Cancer Fund
    Open grant
  • 2003
    Zeiss Cell Observer Video Microscopy System
    NHMRC Equipment Grant
    Open grant
  • 2002 - 2003
    Mitotic regulation of the Ras/Raf/MEK/ERK pathway
    Queensland Cancer Fund
    Open grant
  • 2001 - 2002
    NHMRC Equipment Grant 2000
    NHMRC Equipment Grant
    Open grant
  • 2000 - 2001
    Does increased p21 WAF1 expression effect the mechanism of histone deacetylase inhibitor-induced cell death?
    UQ New Staff Research Start-Up Fund
    Open grant

Supervision

Availability

Professor Brian Gabrielli is:
Available for supervision

Before you email them, read our advice on how to contact a supervisor.

Available projects

  • Identifying the molecular basis for defective checkpoints in melanoma

  • Targeting defective cell cycle responses to ultraviolet radiation and TopoII inhibitors in melanoma

  • Defining the molecular changes in moles underpinning morphological changes detectable by non-invasive imaging techniques to improve their diagnostic and prognostic ability for early stage melanoma

Supervision history

Current supervision

  • Doctor Philosophy

    Enhancing immune responses to cancer

    Principal Advisor

    Other advisors: Honorary Professor John Hooper, Dr Jazmina Gonzalez Cruz

  • Doctor Philosophy

    AURKi enhances replication stress targeted by CHK1i in p53 and RB defective cells

    Principal Advisor

  • Doctor Philosophy

    Assessment of cell cycle phase-dependent immunogenicity of melanoma treated with the proteasome inhibitor bortezomib

    Associate Advisor

    Other advisors: Professor Nikolas Haass

  • Doctor Philosophy

    Modulating phenotypic melanoma heterogeneity and lymphocyte infiltration to improve both targeted and immune therapy

    Associate Advisor

    Other advisors: Dr Janin Chandra, Professor Nikolas Haass

Completed supervision

Media

Enquiries

Contact Professor Brian Gabrielli directly for media enquiries about:

  • Anti-cancer drugs
  • Cancer - drugs to prevent
  • Cancer - skin
  • Cancer - treatment
  • Cell cycle
  • Drugs - anti-cancer
  • Melanoma
  • Mitosis
  • Radiation - ultraviolet
  • Skin cancer
  • Sun cancer
  • Ultraviolet radiation
  • UV rays

Need help?

For help with finding experts, story ideas and media enquiries, contact our Media team:

communications@uq.edu.au